Dr. Dholaria on Patient Characteristics in the MagnetisMM-1 Trial in Multiple Myeloma

In Partnership With:

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Bhagirathbhai Dholaria, MBBS, assistant professor of medicine, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses patient characteristics in the phase 1 MagnetisMM-1 trial (NCT03269136) in relapsed/refractory multiple myeloma.

A majority of phase 1 studies evaluating bispecific T-cell engagers are evaluating similar groups of heavily pretreated patients with multiple myeloma, Dholaria says. The MagnetisMM-1 study ​evaluated the bispecific antibody elranatamab (PF-06863135) alone and in combination with immunomodulatory agents, such as lenalidomide (Revlimid) and pomalidomide (Pomalyst), in patients with relapsed/refractory multiple myeloma.

In the study, nearly all patients were exposed to prior monoclonal antibodies, including CD38-directed monoclonal antibodies, such as daratumumab (Darzalex) and isatuximab-irfc (Sarclisa), Dholaria adds.

Moreover, a proportion of patients had received prior antibody-drug conjugates, such as belantamab mafodotin-blmf (Blenrep), or prior CAR T-cell therapy, Dholaria continues. Patients had received prior BCMA-directed therapies, but were intolerant of or progressed onthem, Dholaria concludes.

Related Videos
View All
Related Content